Chopp M. Simvastatin enhances bone marrow stromal cell differentiation into endothelial cells via notch signaling pathway.
BONE MARROW STROMAL CELLS (BMSCs) are capable of differentiating into multiple cell lineages, including mesenchymal tissues (chondrocytes and adipocytes) and other lineages such as hepatocytes, cardiac/skeletal myocytes, and neurons after transplantation into animals (16, 31) . BMSCs are also able to differentiate into endothelial cells in vitro in the presence of growth factors, such as vascular endothelial growth factor (VEGF) (31) , or in vivo following transplantation and blastocyst injection (18, 30, 35, 41) . However, mechanisms underlying the endothelial differentiation process have rarely been investigated. VEGF regulates endothelial differentiation through different pathways such as the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and Notch signaling pathways (17, 41) . There is evidence demonstrating that the Notch signaling pathway drives arterial differentiation by switching the output of the inductor to a differentiation cue (38) .
The Notch signaling pathway is a well-known signaling mechanism that accounts for lineage diversification in many systems (14) and regulates the differentiation of a variety of cell lineages during embryonic and adult life (5, 23) . The mammalian family of Notch receptors consists of four members, Notch1 through Notch4, whereas the Notch ligand family is composed of five members: Jagged1/2 and Delta-like ligand 1 (DLL1), DLL3, and DLL4. Notch receptors are single-pass transmembrane proteins. Under physiological conditions, the ligand expressed on one cell binds to a Notch receptor expressed on a neighboring cell, which is proteolytically cleaved by the ␥-secretase complex, leading to the formation of the NICD (intracellular cleavage fragment of Notch), which translocates to the nucleus of the receiving cells and consequently activates downstream transcript factors. The Notch signaling cascade has been found to direct cells toward various differentiation fates, including gliogenesis (27, 40) and cardiac differentiation (22) . It can also stabilize arterial endothelial fate and angiogenesis (8) . Activation of Notch signaling by DLL4, a notch ligand, boosts arterial differentiation from human multipotent adult progenitor cells both in vitro and in vivo (1) .
Simvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that is widely used in the treatment and prevention of atherosclerosis as a cholesterollowering agent (37) . However, the benefits of simvastatin appear to go beyond its lipid-lowering effects. Many biological effects of statins, such as differentiation, apoptosis, proliferation, migration, anti-inflammatory actions, and atherosclerotic plaque stabilization can be derived from cholesterol-independent mechanisms (20, 21, 32, 33) . Recent studies have demonstrated that simvastatin enhances differentiation of endothelial progenitor cells into endothelial cells (32) . Statins also regulate Notch signaling activity (4) . In the present study, we examined whether simvastatin induces differentiation of rat BMSCs into endothelial cells via a Notch signaling pathway. Our results show that simvastatin promotes endothelial differentiation from BMSCs by activating the Notch signaling path-way. Inhibition of Notch signaling activation suppresses endothelial cell differentiation from BMSCs, suggesting that the Notch signaling pathway plays a crucial role in the differentiation process.
MATERIALS AND METHODS
BMSC cell culture. Rat BMSCs (R-048, P4; Cognate BioServices, Baltimore, MD) were incubated in HyQ MEM Alpha Modification (HyClone, Logan, UT) with 20% fetal bovine serum (GIBCO, Grand Island, NY) and 1% antibiotins (penicillin streptomycin; GIBCO). Cells were maintained at 37°C in 5% CO 2-95% ambient mixed air and split every 2-3 days. All cells were used within passage 8.
Endothelial differentiation from BMSCs. Rat BMSCs were plated at a density of 6,700 cells/cm 2 and were allowed to grow to 90 -100% confluence in full media before being switched to low-serum differentiation media [HyQ MEM Alpha Modification media containing 2% FBS (GIBCO) and 1% antibiotic-antimyotic]. Previous studies revealed that relatively low concentrations of simvastatin promote osteoblastic differentiation. The most significant effects of simvastatin on differentiation were observed at a concentration no higher than 10 Ϫ6 M in vitro (3, 25, 43) . In our present study, the maximum effect of simvastatin on endothelial differentiation from BMSCs was obtained at the concentration of 5 ϫ 10 Ϫ7 M. Therefore, we used this concentration for the following experiments. To examine its effects on the differentiation of BMSCs, simvastatin (Merck, Somerset, NJ) was added to the differentiation media at the final concentration of 0.5 M. BMSCs treated with 20 ng/ml VEGF165 (R&D systems) for 7 days were used as positive control. ␥-Secretase inhibitor IX (DAPT), a ␥-secretase inhibitor, blocks Notch signaling activity (12) . Therefore, DAPT (Calbiochem) (at a final concentration of 20 g/ml) was used for inhibiting Notch signaling pathway. Experimental groups include 1) 2% FBS only as the control group; 2) ϩsimvastatin 0.5 M; 3) ϩsimvastatin 0.5 M ϩ ␥-secretase inhibitor 20 g/ml; and 4) ϩsimvastatin 0.5 M ϩ Notch1 siRNA. Cells were maintained at 37°C in 5% CO 2-95% ambient mixed air for 7 days before harvest. Media was changed every 48 -72 h.
Knockdown of Notch1 gene expression in BMSCs. Notch1 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) was transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following a standard protocol. Briefly, normal BMSCs were plated out in 10-cm plates and allowed to culture until they were 80% confluent. They were then transfected with 8 g Notch1 siRNA or 8 g scrambled siRNA (Santa Cruz Biotechnology) in serum-free media for 6 h. Afterwards, HyQ MEM Alpha Modification media ϩ 20% FBS were added, and cells were incubated overnight. Media was changed the next day, and 24 h later cells were passed for subsequent experiments. BMSCs were harvested 48 h after culture, and Notch1 gene expression was measured by real-time PCR.
Capillary-like tube formation assay. The method we used is based on Haralabopoulos et al. (13) . BMSCs were treated with 1) differentiation media (2% FBS) as a control; 2) differentiation media with 0.5 M simvastatin; or 3) differentiation media with 20 ng/ml VEGF for 7 days. BMSCs were then used for capillary-like tube formation assays. Briefly, 0.1 ml growth factor-reduced Matrigel (Becton Dickinson, San Jose, CA) was added per well of a 96-well plate, and BMSCs (control, simvastatin treated, and VEGF treated) were placed and incubated in serum-free HyQ media for 4 h. All assays were performed in n ϭ 6/group. For quantitative measurements of capillary tube formation, Matrigel wells were digitized under a ϫ4 objective (Olympus BX40) for measurement of total tube length of capillary tube formation using a video camera (Sony DXC-970MD) interfaced with the MCID image analysis system (Imaging Research, St. Catharines, Canada). Tracks of endothelial cells organized into networks of cellular cords (tubes) were counted and averaged in randomly selected three microscopic fields (36) .
Proliferation assay. For measurement of BMSC proliferation, BMSCs were plated at 5,000 cells/well in a 96-well plate (Corning). Cells were allowed to grow in complete HyQ media for 16 h and were then switched to differentiation media containing: 1) 2% FBS only; 2) 2% FBS ϩ 0.5 M simvastatin; or 3) 2% FBS ϩ20 ng/ml VEGF for 48 h. MTS solution (Promega, Madison, WI) was then added into each of the wells. Thereafter, cells were incubated for 2 h at 37°C, and results were obtained at a wavelength of 490 nm using an ELISA plate reader.
Quantitative RT-PCR. Total RNA was extracted from cells using TRIzol (Invitrogen) following a standard protocol (24) . Contaminating DNA was eliminated by two sequential steps of DNase (Invitrogen) treatment. The mRNA was reverse-transcribed, and cDNA underwent 40 rounds of amplification (ABI PRISM 7000, Applied Biosystems, Foster City, CA) with the following reaction conditions: 40 cycles of a two-step polymerase chain reaction (95°C for 15 s and 60°C for 60 s) after initial denaturation (50°C for 2 min and 95°C for 10 min) with 1 l of DNA solution, 2ϫSYBR green PCR master mix reaction buffer (24) . Each sample was tested in triplicate, and relative gene expression data were analyzed using the 2 Ϫ⌬⌬CT method. The authenticity and size of PCR products were confirmed by melting curve analysis (using software provided by Perkin-Elmer). The mRNA levels were normalized using the GAPDH housekeeping gene and compared with the mRNA levels of the control group. The primers used for amplication are listed in the Table 1 .
Western blotting analysis. Protein was isolated from cultured cells with TRIzol (Invitrogen) following standard protocol. Protein concentrations were determined by a BCA protein assay kit (Pierce, Rock- Table 1 . Primers used for quantitative RT PCR
vWF, von Willebrand factor; VE, vascular endothial; KDR, kinase insert domain receptor; DLL, Delta-like ligand; Hes-1 and Hes-5, hairy and enhancer of split 1 and 5, respectively. ford, IL). Cell lysates (30 g protein/lane) were loaded on a 10% sodium dodecyl sulfate-polyacrylamide gel (Bio-Rad) and subsequently transferred to nitrocellulose membranes after electrophoresis. Membranes were treated with blocking buffer (5% skimmed milk in TBS-T: 25 mm Tris ⅐ HCl, pH 8.0, 125 mm NaCl, 0.1% Tween 20) for 1 h at room temperature, followed by incubation with primary antibodies at 4°C for 16 h. Primary antibodies used here include vWF (1:1,000 dilution; Daco, Carpinteria, CA), VEGF-receptor2 (1:500 dilution; Flk-1, Santa Cruz Biotechnology), and NICD that recognizes Notch cleavage as a result of ligand binding (1:1,000 dilution; Abecam, Cambridge, MA). The membranes were washed three times with TBS-T and then incubated with horseradish peroxidase-conjugated secondary antibodies (1:10,000 dilution) in blocking buffer for 1 h. Signals were developed with Western blotting luminal reagent (Santa Cruz Biotechnology). Normalization of results was ensured by running parallel Western blots with ␤-actin antibody (Abecam) at a dilution of 1:10,000. The optical density was quantified using an image processing and analysis program (Scion image, Ederick, MA).
Immunostaining. BMSCs were cultured on coverslides in 24-well plates. Cells were allowed to grow until 90 -95% confluence and then switched to differentiation media, with 2% FBS, 0.5 M simvastatin, or 0.5 M simvastatin plus ␥-secretase inhibitor. After culture for 7 days, cells were fixed in 4% paraformaldehyde and permeabilized before addition of antibodies. Primary antibodies against VE-cadherin (Santa Cruz Biotechnology) were used at a dilution of 1:50. Fluorescein isothiocyanate (Calbiochem) was used as a second antibody. Samples incubated with second antibody only were used as negative control. Nuclei were identified by 4-6-diamidino-2-phenylindole dihydrochloride (1:10,000; Molecular Probes, Eugene, OR). The percentage of VE-cadherin-positive cells were counted using MCID software (Imaging Research, Saint Catharines, ON, Canada).
Statistical analysis. Data are expressed as means Ϯ SE for all experiments, and a P Ͻ 0.05 was considered statistically significant. Statistical analysis was performed using two-sample t-test (SlideWrite 5.0 32-Bit Edition, Advanced Graphics Software, Encinitas, CA).
RESULTS

Simvastatin enhances differentiation of BMSCs into endothelial cells.
To test whether simvastatin induces BMSCs differentiation into endothelial cells, we examined the time course of endothelial-specific markers gene expression in BMSCs at days 0, 1, 3, and 7 after treatment with low-serum medium or low-serum medium plus 0.5 M simvastatin. The transcript expression of vWF, CD31, and VE-cadherin was maintained at basal levels at days 0 and day 1 in both groups. A slight increase in gene expression of these markers was detected in the simvastatin-treated group at day 3 when compared with control group. Larger changes were observed at day 7, as shown by quantitative RT-PCR analysis, where simvastatin significantly increased the transcriptional expression of endothelial-specific markers including vWF, CD31 (PECAM), VEcadherin, Flk-1, and Flt-1 (2.1 Ϯ 0.1-, 2.3 Ϯ 0.2-, 4.6 Ϯ 0.4-, 2.3 Ϯ 0.2-, and 3.0 Ϯ 0.4-folds, respectively) when compared with the low-serum control group (Fig. 1A) .
To confirm the effect of simvastatin on endothelial differentiation of BMSCs at day 7, we examined the protein expression of endothelial markers in the differentiating cells. We observed an upregulation in protein expression of endothelialspecific markers, including vWF and Flk-1, by Western blot analysis in the BMSCs on day 7 in the presence of simvastatin (Fig. 1B) . Normalization of the results showed a significant difference between the simvastatin group and the control group (Fig. 1C) . Furthermore, immunofluorescence staining demonstrated a significant upregulation of VE-cadherin protein expression in BMSCs treated with simvastatin for 7 days (7.7 Ϯ 0.2%) compared with that of the control group (1.0 Ϯ 0.09%) (see Fig. 7, A and B) . These observations suggest that simvastatin robustly enhances endothelial differentiation of BMSCs.
To rule out the possible effect of cell proliferation on simvastatin-mediated BMSCs differentiation, we examined the proliferation rate of BMSCs under treatment with simvastatin for 48 h. Low-serum differentiation media alone and low- serum differentiation media with 20 ng/ml VEGF were used as controls. Our results demonstrate that there is no significant difference in the proliferation rate among control, simvastatin-, and VEGF-treated groups ( Fig. 2A) , indicating that cell proliferation does not influence simvastatin-induced BMSCs endothelial differentiation.
To test whether the differentiated BMSCs possess endothelial cell function after 7 days of simvastatin treatment, capillary tubelike formation assays were performed in vitro. We found that capillary tube formation of differentiating BMSCs significantly increased by 52 Ϯ 0.6% after 7 days of simvastatin treatment when compared with that of the low-serum alone control group (Fig. 1D) .
VEGF is important in promoting endothelial differentiation from multipotent stem cells (6, 9, 42) . Therefore, we compared endothelial differentiation from BMSCs under conditions of simvastatin and VEGF treatment. Our results showed a 1.32 Ϯ 0.06-fold increase of vWF protein expression in the VEGF group when compared with the simvastatin group (P Ͻ 0.01) at day 7 (Fig. 2B) . However, we did not observe a significant difference in tube formation capacity of the treated cells between the two groups (Fig. 1D ). These data indicate that simvastatin and VEGF both induce endothelial cell differentiation in a comparable manner.
Collectively, our results indicate that simvastatin promotes BMSCs to differentiate into functional endothelial cells. We therefore proceeded to investigate the mechanisms regulating the differentiation process enhanced by simvastatin.
The notch signaling pathway is activated in BMSCs treated with simvastatin. Notch signaling is involved in a number of cell functions, such as differentiation, proliferation, and apoptosis (5). Therefore, we examined whether Notch signaling plays a role in simvastatin-induced differentiation of BMSCs into endothelial cells. Since expression of NICD is a key step in activation of the Notch signaling pathway, we first closely monitored the protein expression profile of the cleaved Notch1 (NICD) at days 0, 1, 3, and 7. We used low-serum medium as a control for each time point. Consistent with the demonstrated endothelial differentiation time course, NICD protein expression slightly increased after a 24-h treatment with simvastatin compared with that of the low-serum group. A similar increase of cleaved NICD was seen at day 3 (Fig. 3) . Additionally, we observed a more significant upregulation of NICD at day 7, where the NICD protein expression dramatically increased with simvastatin compared with that of the low-serum alone control group. Normalization of NICD protein expression with ␤-actin showed a 2.7 Ϯ 0.07-fold increase in the simvastatintreated group compared with the low-serum control group (Fig.  3, A and B) .
Next, we examined gene expression of Notch signaling components at day 7 after initiation of differentiation. Quantitative RT-PCR showed that the transcript levels of DLL4, Notch1, and Notch4 increased significantly when compared with the nontreatment control group (P Ͻ 0.05), whereas no significant difference was found in mRNA levels of Jagged1 and Notch2 between the two groups (Fig. 4) . ␥-Secretase plays important roles in Notch signaling activation (15, 19) . Presenilin-1 (PS-1) can be activated by atorvastatin (4) . Therefore, we examined gene expression of PS-1 after 7 days of treatment. Not surprisingly, a 1.67 Ϯ 0.66-fold upregulation of PS-1 (P Ͻ 0.01 vs. low-serum alone group) was observed in the simvastatin-treated group, suggesting that increased PS-1 increases Notch cleavage in this culture system. The upregulated transcript levels of PS-1 can be reversed by the blockage of Notch signaling with the r-secretase inhibitor (Fig. 5A) .
Hes basic-helix-loop-helix (bHLH) transcription factors, such as Hes-1 and Hes-5, are downstream targets of Notch signaling that play important roles in cell differentiation (10) . Therefore, we further examined gene expression of these transcript factors at day 7. We found that Hes-1 expression remained at basal levels (P Ͼ 0.05), whereas Hes-5 expression significantly increased by 2.5 Ϯ 0.075-fold following the simvastatin treatment when compared with that of the control group (P Ͻ 0.01). The transcript levels of Hes-5 was thereafter reversed by the blockage of Notch signaling with the rsecretase inhibitor (Fig. 5B) .
Collectively, these results suggest that simvastatin treatment of BMSCs increases BMSC differentiation into endothelial cells as well as promotes Notch signaling pathway activity.
Inhibition of Notch signaling by a ␥-secretase inhibitor abolishes the simvastatin-induced endothelial differentiation from BMSCs. To further investigate whether the Notch signaling pathway mediates the differentiation process, we examined the effect of a specific inhibitor of ␥-secretase, which consequently blocks the cleavage of Notch and the production of NICD, on the differentiation of BMSCs into endothelial cells. Western blot analysis showed that simvastatin-induced NICD expression was reduced by 34 Ϯ 4.3% (P Ͻ 0.01) in the presence of the ␥-secretase inhibitor (Fig. 6A) . Normalization of the protein expression was demonstrated in Fig. 6B . The transcript levels of endothelial-specific markers, including vWF, VE-cadherin, and Flk-1 significantly decreased by 21.5 Ϯ 3.9%, 52.4 Ϯ 2.4%, 24.2 Ϯ 2.3%, respectively, in the BMSCs cultured with simvastatin in the presence of the ␥-secretase inhibitor (Fig. 6C) . Accordingly, simvastatin-in- duced protein expression of vWF and Flk1 at day 7 was dramatically downregulated by the addition of the ␥-secretase inhibitor (Fig. 6D) , as revealed by Western blot analysis. Normalization of protein expression showed that endothelialspecific markers vWF and Flk-1 were downregulated by 67.5 Ϯ 0.4% and 96 Ϯ 0.3%, respectively (Fig. 6E) . Immunofluorescence staining demonstrated that protein expression of VE-cadherin was completely abolished by the ␥-secretase inhibitor. The percentage of VE-cadherin-positive cells decreased from 7.7 Ϯ 0.2% to 1.1 Ϯ 0.2% (P Ͻ 0.01; Fig. 7) . Hence, inhibition of NICD expression and the Notch signaling pathway by the ␥-secretase inhibitor leads to decreased simvastatin-induced endothelial differentiation of BMSCs.
Inhibition of Notch signaling by Notch1 siRNA inhibits simvastatin-induced endothelial differentiation from BMSCs.
To further show that Notch signaling participates in simvastatin-induced endothelial differentiation of BMSCs, we introduced Notch1 siRNA into our study. Our data showed that Notch1 siRNA significantly decreased Notch1 mRNA expression by 41 Ϯ 4.2% compared with that of wild-type BMSCs and by 34 Ϯ 4.7% when compared with that of scrambled controls. There was no significant difference between scrambled controls and wild-type BMSCs (Fig. 8A) . Knockdown of Notch1 gene expression significantly decreased simvastatininduced NICD expression by 44 Ϯ 3.3% in transfected BMSCs compared with wild-type BMSCs (Fig. 8, B and C) . Accordingly, mRNA expression of the endothelial-specific markers (vWF, VE-cadherin, and Flk-1) induced by simvastatin dramatically decreased in transfected BMSCs by 68.3 Ϯ 2.3%, 43.1 Ϯ 2.2%, 30.7 Ϯ 3.2%, respectively, when compared with those of wild-type BMSCs, as revealed by quantitative RT-PCR (Fig. 8D) . These data further suggest that Notch signaling is critical for simvastatin-induced endothelial differentiation from rat BMSCs.
Taken together, these data suggest that simvastatin promotes differentiation of BMSCs into endothelial cells. Furthermore, inhibition of Notch signaling pathway attenuates simvastatininduced endothelial cell differentiation from BMSCs. showed that DLL4, Notch1, and Notch4 increased significantly when compared with control group, whereas no significant difference was found in mRNA levels of Jagged1 and Notch2 between the two groups. Results shown are means Ϯ SE from at least three independent experiments. 
DISCUSSION
The present study demonstrates that simvastatin induces differentiation of BMSCs into endothelial cells after 7 days of treatment as well as promotes Notch signaling pathway activity. Inhibition of the Notch signaling pathway abolishes the ability of simvastatin-induced endothelial cell differentiation. Therefore, the Notch signaling pathway is likely to play a key role in endothelial differentiation from BMSCs triggered by simvastatin.
Statins are small molecule inhibitors of HMG-CoA reductase and can effectively diminish endogenous cholesterol levels. However, there is growing evidence for additional benefits of statins in cell differentiation, apoptosis, proliferation, and migration, which are independent of lipid/cholesterol lowering (20, 21, 32, 33) . Of the several kinds of HMG-CoA reductase inhibitors, simvastatin has been proven to be one of the most effective reagents on differentiation of multiple cell lineages (3, 29) . Simvastatin stimulates in vivo bone formation when injected subcutaneously over the mouse calvaria (28) and enhances osteogenesis in MC3T3-E1 cells (a clonal preosteoblastic cell line derived from mouse calvaria), human marrow stromal cells, as well as human periodontal ligament cells (3, 25, 43) . There is also evidence demonstrating that simvastatin enhances endothelial differentiation from human peripheral blood mononuclear cells (32) . In addition, simvastain elicits a strong and rapid stellation in astrocytes, a typical differentiation phenomenon that normally occurs during CNS development (26) .
In our study, we observed that consistent stimulation with 0.5 M simvastatin in low-serum conditions induces BMSCs to differentiate into endothelial cells, whereas a short exposure to simvastatin is not sufficient to induce differentiation, as indicated by gene and protein expression profiling of endothelial-specific markers. VEGF is a multi-tasking cytokine that is essential for endothelial cell differentiation from multipotent stem cells (44) . Furthermore, simvastatin and VEGF had similar effects on inducing endothelial differentiation from BMSCs, indicating that simvastatin is capable of triggering the differentiation of BMSCs into functional endothelial cells.
We next investigated mechanisms involved in this process. We demonstrated in our previous study that the Notch signaling pathway is activated by a statin (4). The Notch signaling pathway influences cell fate decisions, such as cell differentiation, survival/apoptosis, and cell cycle in both physiological and pathological circumstances (5) . Therefore, we hypothesized that simvastatin enhances endothelial differentiation from BMSCs through the Notch signaling pathway. Surprisingly, we found that simvastatin increases expression of the major components of the Notch signaling pathway such as DLL4, PS-1, Notch1, and Notch 4 in BMSCs and subsequently leads to the expression of NICD. Consistent with Notch signaling activation, Hes-5, but not Hes-1, is significantly upregulated by simvastatin at day 7. As Notch effectors, Hes-1 and Hes-5 are believed to play essential roles in the development of multiple organs, including nervous system, sensory organs, pancreas, and endocrine cells (8) . Based on our data, we then speculated that Hes-5 might be one of the key downstream effectors that is important in Notch signaling-regulated endothelial differentiation of BMSCs. Blocking of the Notch signaling pathway by DAPT, a cell-permeable ␥-secretase inhibitor (39), or Notch1 siRNA, significantly inhibited endothelial differentiation and also resulted in downregulation of Notch signaling components. Previous studies suggest that Notch signaling works as an inhibition mechanism that maintains cells in an undifferentiated state (2) . Nonetheless, Notch signaling activation has now been observed to trigger differentiation of multiple cell types. The differentiation of at least three types of glial cells, including Schwann cells (27) , radial glia (11) , and Muller cells (10) is induced by the activation of the Notch signaling pathway. Notch signaling activation is also found to precede heart regeneration in zebra fish (34) . NICD transfection followed by trophic factor induction efficiently induced BMSCs with neuronal characteristics (7) . Moreover, Notch activation facilitates cardiac cell differentiation from human circulating progenitor cells (22) . Our results suggest that the Notch signaling pathway serves as a strong positive regulator of the simvastatin-induced endothelial differentiation from BMSCs.
In conclusion, these data indicate that simvastatin induces endothelial differentiation from BMSCs via the Notch signaling pathway. These results suggest a novel pathway for endothelial differentiation from stem cells. New strategies leading to the activation of Notch signaling pathway may promote angiogenesis and be beneficial in treating vascular injury and ischemic vascular diseases. 
